.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Ravulizumab is a long-acting complement C5 inhibitor designed to reduce the interval burden of treatment compared with eculizumab. Final open-label extension data from the phase 3 CHAMPION MG programme followed adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis for up to four years. Sustained improvements were observed in MG-ADL, quantitative myasthenia measures, quality of life and fatigue. Corticosteroid use also declined during the extension period, and clinical deterioration events were reduced compared with the earlier placebo period. The results support durable efficacy of complement inhibition in AChR-positive generalized MG. Because the extension was open-label, it is not equivalent to a long-term randomized comparison, but it provides useful information about persistence of benefit and safety. For HCPs, ravulizumab is most relevant to patients with generalized MG whose disease remains functionally burdensome despite standard therapy. Vaccination and infection-risk management are essential with complement inhibition, and cost and dosing logistics also influence practical use. The study fits IANCON's focus on myasthenia gravis and the expanding role of targeted immune therapies.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Ravulizumab is a long-acting complement C5 inhibitor designed to reduce the interval burden of treatment compared with eculizumab. Final open-label extension data from the phase 3 CHAMPION MG programme followed adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis for up to four years. Sustained improvements were observed in MG-ADL, quantitative myasthenia measures, quality of life and fatigue. Corticosteroid use also declined during the extension period, and clinical deterioration events were reduced compared with the earlier placebo period. The results support durable efficacy of complement inhibition in AChR-positive generalized MG. Because the extension was open-label, it is not equivalent to a long-term randomized comparison, but it provides useful information about persistence of benefit and safety. For HCPs, ravulizumab is most relevant to patients with generalized MG whose disease remains functionally burdensome despite standard therapy. Vaccination and infection-risk management are essential with complement inhibition, and cost and dosing logistics also influence practical use. The study fits IANCON's focus on myasthenia gravis and the expanding role of targeted immune therapies.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
